Trial Search Results

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eicos Sciences, Inc.

Stanford Investigator(s):


  • Drug: Placebo IV infusion
  • Drug: Iloprost Injection, for intravenous use


Phase 3


Inclusion Criteria:

   - Male or female subjects must be greater than or equal to 18 years of age.

   - Subjects must have a diagnosis of Systemic Sclerosis as defined by the 2013 American
   College of Rheumatology criteria/EULAR criteria

   - Subjects must have a diagnosis or history of Raynaud's Phenomenon, self-reported or
   reported by a physician, with at least a 2-phase color change in finger(s) of pallor,
   cyanosis, and/or reactive hyperemia in response to cold exposure or emotion

   - Subjects must have a minimum of 10 symptomatic Raynaud's Phenomenon attacks,
   documented in the electronic patient-reported outcomes (ePRO) diary, occurring over at
   least 3 separate days of the 3- to 5-day eligibility period

   - Subjects must complete a minimum of 80% of the daily ePRO diary entry during the
   baseline period

   - Female subjects of childbearing potential and male subjects must agree to use
   contraception for the duration of the study.

   - Subjects must be willing and able to comply with the study requirements and give
   informed consent for participation in the study

Exclusion Criteria:

   - Female subjects who are pregnant or breastfeeding

   - Subjects with systolic blood pressure <85 mmHg

   - Subjects with an estimated glomerular filtration rate <15 mL/min/1.73 m2

   - Subjects with an alanine aminotransferase and/or aspartate aminotransferase value >3 ×
   the upper limit of normal at screening

   - Subjects who have a digital ulcer infection within 30 days of screening

   - Subjects with a history of cervical or digital sympathectomy, or botulism toxin
   injections in their hands [for RP or digital ulcers] within 90 days of screening.
   Subjects should not have a planned botulism toxin or sympathectomy during their
   participation in the study.

   - Subjects with gangrene or digital amputation within 6 months of screening

   - Subjects with current intractable diarrhea or vomiting

   - Subjects with a risk of clinically significant bleeding events, including those with
   coagulation or platelet disorders at screening

   - Subjects with a history of major trauma or hemorrhage within 30 days of screening.

   - Subjects with clinically significant chronic intermittent bleeding, such as active
   gastric antral vascular ectasia or active peptic ulcer disease, within 60 days of

   - Subjects who have had any cerebrovascular events (eg, transient ischemic attack or
   stroke) within 6 months of screening

   - Subjects with a history of myocardial infarction or unstable angina within 6 months of
   screening. Subjects should not have a planned coronary procedure during their
   participation in the study

   - Subjects with acute or chronic congestive heart failure (New York Heart Association
   Class III [moderate] or Class IV [severe]) at screening

   - Subjects with a history of more than mild restrictive or congestive cardiomyopathy
   uncontrolled by medication or implanted device

   - Subjects with a history of life-threatening cardiac arrhythmias

   - Subjects with a history of hemodynamically significant aortic or mitral valve disease

   - Subjects with a history of known pulmonary hypertension, pulmonary arterial
   hypertension, or pulmonary veno-occlusive disease

   - Subjects with a history of significant restrictive lung disease, defined as forced
   vital capacity <45% predicted and diffusing capacity of the lungs for carbon monoxide
   <40% predicted (uncorrected for hemoglobin)

   - Subjects with scleroderma renal crisis within 6 months of screening

   - Subjects with a concomitant life-threatening disease with a life expectancy <12 months

   - Subjects who have a clinically significant disorder that, in the opinion of the
   Investigator, could contraindicate the administration of study drug, affect
   compliance, interfere with study evaluations, or confound the interpretation of study

   - Subjects who have taken or are currently taking any parenteral, inhaled, or oral
   prostacyclin or prostacyclin receptor agonists (eg, epoprostenol, treprostinil,
   iloprost, and selexipag) within 8 weeks of screening

   - Subjects who have initiated or had a dose change of any of the following within 2
   weeks of screening: oral, topical, or intravenous (IV) vasodilators (eg, calcium
   channel blockers, phosphodiesterase-5 (PDE5) inhibitors [eg, sildenafil, tadalafil, or
   vardenafil], nitrates, and fluoxetine)

   - Subjects with any history of acetaminophen intolerability (eg, allergic reaction to

   - Subjects with any malignancy that requires treatment during the study period, that has
   required treatment within 1 year of screening (including excision of skin cancer) or
   that is currently not in remission

   - Subjects who have used any investigational medication or device for any indication
   within 30 days or 5 half-lives (whichever is longer)

   - Subjects who have participated in ES-201 or ES-301 studies and were randomized and
   treated with study drug

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting